RESEARCH-USE BIOSIMILAR ANTIBODY
Mezagitamab
Monoclonal antibody · IgG1
Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP).
TARGETCD38
YMonoclonal antibody
CATALOGSC-BS-386
CATALOG NUMBERSC-BS-386
MOLECULAR WEIGHTApprox. 143.7 kDa
PRODUCT FORMATMonoclonal antibody
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP).
Mezagitamab is a recombinant research-use antibody directed against CD38.